With a mean follow-up of 2.6 years, the study demonstrated a 34% reduction in the relative risk (RR) of a composite renal outcome, including dialysis requirement, a decline in glomerular filtration rate (GFR) 7% were initiated on the complementary drug to complete the GLP-1 RA + SGLT-2i combination therapy
Aegis Peptides does not provide advice on dosing, preparation, administration, injection, treatment, clinical use or personal use
Also, data analysis showed that the serum GLP-1 level of patients with newly diagnosed T2DM combined with CAS was significantly reduced compared with the control group
1.0 mL Syringe: 100 units max ideal for large reconstitution volumes or doses over 50 units
Evidence: The strongest data come from a large meta-analysis involving over 100,000 patients
Patients should engage in regular follow-ups with their healthcare provider to assess the effectiveness of the treatment and make necessary adjustments, ensuring that the benefits outweigh any potential risks over time